Interferon Beta-1A

CHEMBL1201562 Phase 4 Onaylandı Protein
Half-Life
Bioavailability
Protein Binding
Molecular Weight
g/mol
LogP
Phase
4

This recombinant interferon used to treat relapsing forms of multiple sclerosis (MS) works by modulating the immune system to reduce the frequency and severity of relapses and slow disability progression. It is thought to reduce the migration of immune cells across the blood-brain barrier and suppress inflammatory activity in the nervous system. It is administered by intramuscular or subcutaneous injection.

Terapötik Alanlar

Etki Mekanizması

As a recombinant protein, it replicates the function of the naturally occurring human protein, supplementing or replacing deficient endogenous production to restore normal physiological activity.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mekanizma

As a recombinant protein, it replicates the function of the naturally occurring human protein, supplementing or replacing deficient endogenous production to restore normal physiological activity.

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Sıkça Sorulan Sorular

This recombinant interferon used to treat relapsing forms of multiple sclerosis (MS) works by modulating the immune system to reduce the frequency and severity of relapses and slow disability progression. It is thought to reduce the migration of immune cells across the blood-brain barrier and suppress inflammatory activity in the nervous system. It is administered by intramuscular or subcutaneous injection.

As a recombinant protein, it replicates the function of the naturally occurring human protein, supplementing or replacing deficient endogenous production to restore normal physiological activity.

Yes, Interferon Beta-1A is an approved drug. It has reached clinical phase 4. It is classified as a Protein.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1201562. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.

Tıbbi Sorumluluk Reddi

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.